{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:12:47Z","timestamp":1779927167049,"version":"3.53.1"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Developments in genomic profiling introduced larger gene panels with decreasing sequencing costs. Although the feasibility of comprehensive genomic profiling (CGP) has been demonstrated, its health economic impact remains uncertain.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To provide insights into the costs related to clinical implementation of CGP-based advice in a large prospective cohort.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In this economic evaluation of a prospective Belgian multicenter observational study (Belgian Approach of Local Laboratory Extensive Tumor Testing [BALLETT]), a decision tree was designed to illustrate costs and outcomes adopting a diagnostic time horizon. The evaluation also included a future evaluation scenario comparing standard-of-care diagnostics with upfront CGP. This study included patients with advanced solid tumors enrolled in the BALLETT study between May 1, 2021, and October 31, 2023. Analyses were conducted using the entire study population and individual tumor types.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n CGP followed by molecular tumor board (MTB) discussions to formulate treatment recommendations.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Model outcomes were total diagnostic costs and the percentage of patients with actionable targets, MTB recommendations, and matched treatments. Incremental cost-consequence ratios were calculated.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 814 patients with advanced tumors (mean [SD] age, 60.8 [12.3] years; 452 female [55.5%]) participated in the study. The mean diagnostic costs for patients of the BALLETT cohort were \u20ac2147. Actionable targets were identified in 621 patients (76%), MTB recommendations were provided in 529 patients (65%), and 123 patients (15%) received a matched treatment. The diagnostic cost to match a CGP-matched treatment was \u20ac14\u202f249. This cost varied between specific tumor types (\u20ac9952 for lung cancer to \u20ac20\u202f377 for colon cancer). Sensitivity analyses showed that these cost-consequence ratios are most influenced by diagnostic cost and the uptake of MTB recommendations. In the scenario comparing upfront CGP and standard-of-care diagnostics, the incremental diagnostic cost to match a treatment was estimated to be slightly lower (\u20ac13\u202f936).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This economic evaluation of CGP in patients with advanced cancer estimated the diagnostic cost to match a treatment. CGP-matched treatment cost and benefit requirements were estimated under which CGP was cost-effective, thereby providing health care decision-makers with relevant economic evidence for decision-making.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.48538","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:00:39Z","timestamp":1765468839000},"page":"e2548538","source":"Crossref","is-referenced-by-count":2,"title":["Economic Evaluation of Comprehensive Genomic Profiling in an Advanced Solid Cancer Population"],"prefix":"10.1001","volume":"8","author":[{"given":"Lucas F.","family":"van Schaik","sequence":"first","affiliation":[{"name":"Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands"},{"name":"Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Maes","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Diagnostics, Department of Clinical Biology, Jessa Hospital, Hasselt, Belgium"},{"name":"Faculty of Medicine and Life Sciences, Limburg Clinical Research Centre, University of Hasselt, Hasselt, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter-Jan","family":"Volders","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Diagnostics, Department of Clinical Biology, Jessa Hospital, Hasselt, Belgium"},{"name":"Faculty of Medicine and Life Sciences, Limburg Clinical Research Centre, University of Hasselt, Hasselt, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Froyen","sequence":"additional","affiliation":[{"name":"Laboratory for Molecular Diagnostics, Department of Clinical Biology, Jessa Hospital, Hasselt, Belgium"},{"name":"Faculty of Medicine and Life Sciences, Limburg Clinical Research Centre, University of Hasselt, Hasselt, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Aftimos","sequence":"additional","affiliation":[{"name":"H\u00f4pital Universitaire de Bruxelles, Universit\u00e9 Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[{"name":"H\u00f4pital Universitaire de Bruxelles, Universit\u00e9 Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedwig M.","family":"Blommestein","sequence":"additional","affiliation":[{"name":"Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim H.","family":"van Harten","sequence":"additional","affiliation":[{"name":"Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands"},{"name":"Department of Health Technology and Services Research, University of Twente, Enschede, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valesca P.","family":"Ret\u00e8l","sequence":"additional","affiliation":[{"name":"Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands"},{"name":"Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"issue":"1","key":"zoi251304r1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13073-019-0703-1","article-title":"Molecular profiling for precision cancer therapies.","volume":"12","author":"Malone","year":"2020","journal-title":"Genome Med"},{"key":"zoi251304r2","article-title":"Implementation of whole-genome and transcriptome sequencing into clinical cancer care.","volume":"6","author":"Cuppen","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"zoi251304r3","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104441","article-title":"Factors for a broad technology assessment of comprehensive genomic profiling in advanced cancer, a systematic review.","volume":"202","author":"van Schaik","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"zoi251304r4","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jamaoncol.2016.2129","article-title":"Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis.","volume":"2","author":"Schwaederle","year":"2016","journal-title":"JAMA Oncol"},{"issue":"5","key":"zoi251304r5","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11523-022-00910-0","article-title":"Comparing survival outcomes for advanced cancer patients who received complex genomic profiling using a synthetic control arm.","volume":"17","author":"O\u2019Haire","year":"2022","journal-title":"Target Oncol"},{"issue":"1","key":"zoi251304r6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104089","article-title":"Longer survival with precision medicine in late-stage cancer patients.","volume":"10","author":"Mapendano","year":"2025","journal-title":"ESMO Open"},{"key":"zoi251304r7","doi-asserted-by":"crossref","first-page":"S1202","DOI":"10.1016\/j.annonc.2024.08.2245","article-title":"LBA7 The Rome trial from histology to target: the road to personalize targeted therapy and immunotherapy.","volume":"35","author":"Botticelli","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi251304r8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41698-025-00858-0","article-title":"A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer.","volume":"9","author":"Volders","year":"2025","journal-title":"NPJ Precis Oncol"},{"issue":"5","key":"zoi251304r9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40273-025-01470-7","article-title":"Towards recommendations for cost-effectiveness analysis of predictive, prognostic, and serial biomarker tests in oncology.","volume":"43","author":"Kramer","year":"2025","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"zoi251304r10","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1186\/s12885-024-13167-9","article-title":"Relevant factors for policy concerning comprehensive genomic profiling in oncology: stakeholder perspectives.","volume":"24","author":"van Schaik","year":"2024","journal-title":"BMC Cancer"},{"issue":"4","key":"zoi251304r11","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jval.2021.09.017","article-title":"Cost-effectiveness of tumor genomic profiling to guide first-line targeted therapy selection in patients with metastatic lung adenocarcinoma.","volume":"25","author":"Dong","year":"2022","journal-title":"Value Health"},{"issue":"4","key":"zoi251304r12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40273-023-01344-w","article-title":"Exploring the cost effectiveness of a whole-genome sequencing-based biomarker for treatment selection in patients with advanced lung cancer ineligible for targeted therapy.","volume":"42","author":"Mfumbilwa","year":"2024","journal-title":"Pharmacoeconomics"},{"key":"zoi251304r13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.vhri.2023.08.006","article-title":"Cost-effectiveness of comprehensive genomic profiling in patients with non-small cell lung cancer for the Colombian Health System.","volume":"39","author":"Gamboa","year":"2024","journal-title":"Value Health Reg Issues"},{"issue":"12","key":"zoi251304r14","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s40273-021-01073-y","article-title":"Early cost effectiveness of whole-genome sequencing as a clinical diagnostic test for patients with inoperable stage IIIB,C\/IV non-squamous non-small-cell lung cancer.","volume":"39","author":"Simons","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"zoi251304r15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"1","key":"zoi251304r16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"issue":"4","key":"zoi251304r17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","article-title":"AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users.","volume":"34","author":"Vemer","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"zoi251304r18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/14737167.2021.1917385","article-title":"Micro-costing diagnostics in oncology: from single-gene testing to whole-genome sequencing.","volume":"21","author":"Pasmans","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7","key":"zoi251304r20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/0272989X16686559","article-title":"An overview of R in health decision sciences.","volume":"37","author":"Jalal","year":"2017","journal-title":"Med Decis Making"},{"issue":"1","key":"zoi251304r22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3390\/cancers12010132","article-title":"A trial-based cost-utility analysis of metastasis-directed therapy for oligorecurrent prostate cancer.","volume":"12","author":"De Bleser","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"zoi251304r23","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2214-109X(23)00162-6","article-title":"Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures.","volume":"11","author":"Pichon-Riviere","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"5","key":"zoi251304r25","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jval.2025.02.004","article-title":"Early cost-effectiveness analysis of using whole-genome sequencing for patients with castration-resistant prostate cancer.","volume":"28","author":"Fu","year":"2025","journal-title":"Value Health"},{"issue":"5","key":"zoi251304r26","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/PO.20.00540","article-title":"Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small-cell lung cancer.","volume":"5","author":"Harvey","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"zoi251304r27","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/13696998.2018.1549056","article-title":"Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.","volume":"22","author":"Signorovitch","year":"2019","journal-title":"J Med Econ"},{"issue":"5","key":"zoi251304r28","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-099134","article-title":"Impact of comprehensive genomic profiling and molecular tumour board on costs and access to tailored therapies: real-world observational study.","volume":"15","author":"De Micheli","year":"2025","journal-title":"BMJ Open"},{"issue":"4","key":"zoi251304r29","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102981","article-title":"The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology.","volume":"9","author":"Kubo","year":"2024","journal-title":"ESMO Open"},{"key":"zoi251304r30","article-title":"Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care.","author":"Weymann","year":"2021","journal-title":"J Community Genet"},{"key":"zoi251304r31","doi-asserted-by":"crossref","DOI":"10.1007\/s11523-022-00910-0","article-title":"Comparing survival outcomes for advanced cancer patients who received complex genomic profiling using a synthetic control arm.","author":"O\u2019Haire","year":"2022","journal-title":"Target Oncol"},{"issue":"3","key":"zoi251304r32","article-title":"Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.","volume":"3","author":"Kazmi","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"zoi251304r33","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/annonc\/mdz119","article-title":"Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.","volume":"30","author":"van Waalwijk van Doorn-Khosrovani","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"zoi251304r34","first-page":"601","article-title":"Effect of a collaboration between a health plan, oncology practice, and comprehensive genomic profiling co from the payer perspective.","volume":"25","author":"Reitsma","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"zoi251304r35","doi-asserted-by":"crossref","first-page":"e1225","DOI":"10.1200\/OP.20.01092","article-title":"Effect of clinical trial participation on costs to payers in metastatic non-small-cell lung cancer.","volume":"17","author":"Merkhofer","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"zoi251304r36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41698-022-00343-y","article-title":"Precision medicine: affording the successes of science.","volume":"7","author":"Lu","year":"2023","journal-title":"NPJ Precis Oncol"},{"issue":"5","key":"zoi251304r37","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/2168479018809692","article-title":"Cancer clinical trials: treatment costs associated with a Spanish National Health System institution.","volume":"53","author":"Capdevila","year":"2019","journal-title":"Ther Innov Regul Sci"},{"issue":"4","key":"zoi251304r38","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/hon.2753","article-title":"Drug cost savings in phase III hematological oncology clinical trials in a university hospital.","volume":"38","author":"Herledan","year":"2020","journal-title":"Hematol Oncol"},{"issue":"12","key":"zoi251304r39","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1016\/j.jval.2023.09.1725","article-title":"HTA40 making MCDA \u2018Shiny\u2019 with an adaptive support tool for healthcare decision-making: an application in broad molecular testing with R Shiny.","volume":"26","author":"Coves","year":"2023","journal-title":"Value Health"},{"key":"zoi251304r40","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/CLEP.S242097","article-title":"Synthetic and external controls in clinical trials: a primer for researchers.","volume":"12","author":"Thorlund","year":"2020","journal-title":"Clin Epidemiol"},{"key":"zoi251304r19","unstructured":"Maes? B. CAN.HEAL WP9 Deliverable Report D9.1: National Precision Initiatives. 2025. Accessed October 28, 2025. https:\/\/zenodo.org\/records\/15047664"},{"key":"zoi251304r21","unstructured":"RIZIV. (Hemato-)oncologie: Terugbetaling van moleculair-biologische testen met \u201cNext Generation Sequencing: RIZIV; 2024. Accessed October 28, 2025. https:\/\/www.riziv.fgov.be\/nl\/professionals\/verzorgingsinstellingen-en-diensten\/laboratoria\/hemato-oncologie-terugbetaling-van-moleculair-biologische-testen-met-next-generation-sequencing"},{"key":"zoi251304r24","unstructured":"ComPerMed. Next-generation sequencing guidelines. Accessed October 28, 2025. https:\/\/www.compermed.be\/en\/guidelines."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2842659\/van_schaik_2025_oi_251304_1767730755.09329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:00:20Z","timestamp":1767974420000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2842659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.48538","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]}}}